4/6 pts with PsA have poor sleep quality (!) (PSQI) Asso w/ female, > enthesitis, > dis activity, fatigue, anxiety or depression. 1/2 = no ttmt for insomnia. Multimodal interventions incl psychological support are key! https://t.co/z5V9SKur3G Abstr #0387 #ACR22 @Rheumnow https://t.co/CsTZkHjnn6

• Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Ac…

Pearl: ANCA vasculitis may present initially as a migratory arthritis @RheumNow #ACR22 #Pearls https://t.co/259ZNUcEMB

Systemic autoimmune dx/'CTDs': We attach lots of legacy labels, but most aren't pure/neatly in boxes. We can do better: immunophenotyping: FACS n=235 🇯🇵 unsupervised clustering Within clusters: better phenotypes, varied labels. This has to be the future ABS0506 #ACR22 @RheumNow https://t.co/YUTVN1dWCh

Kirby @colmkirby22 et al. US monitoring in newly diagnosed GCA. US mirrored clinical activity and predicted need for tocilizumab use. @rheumnow #ACR22 Abstr#0479 https://t.co/Ncqi8rZI6K https://t.co/DmzhNyzEfI

• A Prospective Study Evaluating the Utility of Ultrasound in Monitoring Newly-Di…

How age influence PsA clinical phenotype and diag? Late onset PsA associated w/ male, > damage, > arthritis, > BASFI, < diag delay and < SI and enthesitis reports Puche-Larrubia et al from RESPONDIA & REGISPONSER registries. https://t.co/pC21Yv8Nv9 Abstr #0377 #ACR22 @Rheumnow https://t.co/cQRDELO5my

• Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RE…

Complement TRENDS rather than absolute numbers may be more useful in pregnancy @RheumNow #ACR22 #Pearls https://t.co/jz2SzdClfs

Koc et al Female RA patients improve less in terms of disease activity over time. Score worse on HAQ,fatigue,SF-36 PCS, and morning stiffness duration @rheumnow #ACR22 Abstr#241 https://t.co/5HA0m3hNG4 https://t.co/Dx3C9r7FTl

• Inequity in Disease Impact Between Male and Female Rheumatoid Arthritis Patient…

@DiegoBenavent et al: Gender impacts disease outcomes in PsA and SpA. Women > BASDAI, >BASFI, > ASDAS, >ASDAS Hi, and > EQ-5D. Not so surprising considering higher ratio for Fibromyalgia in W ASDAS not asso w/ gender in AxSPA. https://t.co/kBxvAi5qZw Abstr #0381 #ACR22 @Rheumnow https://t.co/vxdtlKpT3l

• Most Disease Outcome Measures but Not ASDAS Are Influenced by Gender in Patient…

We've never been convinced on adjunct therapy in GCA - yet we're still worried about aortic dilatation. Beta-blockers we're def not doing - but impressive retrospective data here. Let's test this properly! ABST0477 #ACR22 @RheumNow (also @seminarthrheum https://t.co/onKW2JKIzo) https://t.co/yHTx29NJNX

• https://www.sciencedirect.com/science/article/abs/pii/S0049017222001688

Black study subjects remain underrepresented in rheumatology clinical trials except for gout. Abs 0089 Continued under-reporting of race and ethnicity in PsA trials. Abs 0090 We can do better #rheumtwitter #ACR22 @RheumNow https://t.co/lzFXxFxgNs and https://t.co/K9dYaaXCg8 https://t.co/VqQe1OCsKg

• Racial Disparities in Rheumatology Clinical Trials - ACR Meeting Abstracts
• Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis -…

Germany based 74 pt #FMF prospective non-interventional, multicenter observational study on Canakinumab - RELIANCE Registry 63% in remission in 2 yrs serious adverse drug reactions - 1.56 per 100 patient years @RheumNow #ACR22 abst#0138

@ericdeinmd is moderating a great session, difficult to treat RA at #ACR22 right now! #rheumpix @RheumNow https://t.co/R5yg3eme6v

Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/y7VWk3lOXD

Culerrier @AKronbichler @TerrierBen et al. AAV induced by anti-thyroid drugs. 45 cases. vs AAV - younger (45 vs 68) More skin (54 vs 25%) Less renal (38 vs 73%) Less severe (BVAS 9 vs 13) Less relapse (HR 0.07). Can rechallenge! @rheumnow #ACR22 Abstr#0436 https://t.co/0i7zj615N6 https://t.co/t7fWCOuUsJ

• Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by…

OPAL data is a gem! Large Australian data studying JAKi use in #rheumatoidarthritis N=5900 Switching JAKi~JAKi-common. As in TNFi 1st line Rx had longer retention & better efficacy than 2nd & subsequent. Median 1st advanced Rx - same in all JAKs 34 MOA @RheumNow #ACR22 abst0274 https://t.co/FQU4AKXwe9